aTyr Pharma completed a $23 million Series C round, which it will use to develop its pre-clinical pipeline, based on physiocrine drugs. The company is headquartered in San Diego. It also has operations in Shanghai and collaborates with China organizations in drug development. In addition, aTyr's Hong Kong subsidiary, Pangu BioPharma, which operates in partnership with Hong Kong University of Science and Technology (HKUST), assists in aTyr's pre-clinical drug development. More details....